Clinical trial · Observational
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
The Role of Adjuvant VaccInation After Conization for the Treatment for Cervical Dysplasia
NCT06611020CI-TRIAL-00081098VITALrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
HPV vaccination has emerged as a strategy to reduce the risk of recurrence oafter excisional treatment. However, only few data are aviable. In this trial the investigators aim to assess the role of HPV vaccination in women traeted for HPV-related lesions
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- treatment of HPV-related disease with or without vaccination
Primary outcomes (1)
- measure
- HPV recurrence
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Treatment of HPV-related disease Exclusion Criteria: * Previous HPV vaccination
References
Publications (1)
- DERIVEDCaia C, De Maria F, Sopracordevole F, Ciavattini A, Casarin J, Ghezzi F, Vizzielli G, Chiappa V, Leone Roberti Maggiore U, Valsecchi C, Scambia G, Raspagliesi F, Corso G, Bogani G. Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia. Eur J Cancer Prev. 2026 May 1;35(3):243-249. doi: 10.1097/CEJ.0000000000000971. Epub 2025 Apr 18. PMID 40277212